GSK to Acquire Sierra Oncology for $1.9 Billion
April 13, 2022
GlaxoSmithKline plc (GSK) has entered into an agreement to acquire late-stage biopharmaceutical company Sierra Oncology, Inc. for $1.9 billion (approximately $55 per share in cash). The acquisition is intended to bring Sierra’s lead asset momelotinib—an investigational targeted therapy for myelofibrosis and anemia—into GSK’s specialty medicines portfolio.
- Buyers
- GlaxoSmithKline plc (GSK)
- Targets
- Sierra Oncology, Inc (Sierra Oncology)
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.